Praveen Tyle

Dr. Tyle brings over 37 years of experience in both large and small pharma and biotech companies, currently serving as President, CEO and Board member of Invectys, Inc, a Immunotherapeutics company based in Houston, Texas. Previously, from 2016-2021, he served as Executive V.P. for Research and Development of the public company, Lexicon Pharmaceuticals, Inc. and from 2013-2016, he served as President, CEO and Board member of Osmotica Pharmaceutical Corp where he led the successful merger of the Company with Avista Partners in 2016. Earlier, Dr. Tyle served as the Corporate Senior Vice President and Chief Scientific Officer of Bausch and Lomb and then as Senior Vice President and Global Head of Business Development and R&D at Novartis OTC. Dr. Tyle has a PhD in Pharmaceutics and Pharmaceutical Chemistry from The Ohio State University and B. Pharmacy (Honors) from the Indian Institute of Technology, BHU.